Hybridan Small Cap Feast

Joiners: Invinity Energy Systems plc (AIM:IES), a leading global manufacturer of utility-grade energy storage has dual listed on the Aquis Stock Exchange.

Leavers: No leavers today.

Banquet Buffet

Ergomed 1,175p  £574.2m (ERGO.L)

The company focused on providing specialised services to the pharmaceutical industry, today announces that John Dawson, CBE has joined the Board as an independent Non-Executive Director and Chair of the Audit Committee.  John Dawson is a highly experienced and globally respected figure in the healthcare sector. Most recently, he was Chief Executive Officer of Oxford Biomedica (LSE: OXB) where, during his 13-year tenure, the business grew into a global market leader in viral vector technologies for cell and gene therapy, delivered multiple high value partnerships and successfully manufactured the life-saving Oxford/ AstraZeneca COVID-19 vaccine. Under Mr. Dawson’s leadership, Oxford Biomedica’s success resulted in it entering the FTSE 250 index in 2020. Subsequently, in the New Year Honours List this year, he was awarded a CBE for services to UK life science, in recognition of the unprecedented speed and success at which Oxford Biomedica delivered the COVID-19 vaccine. Prior to Oxford Biomedica, Mr. Dawson held various senior executive roles including at Cephalon Pharmaceuticals where for most of his tenure he was Managing Director for Europe. Prior to this, he served as the Financial Director for Serono before its acquisition by Merck. Mr. Dawson holds a BSc in Mathematics from Swansea University and is a Chartered Accountant.

Gaming Realms 26.30p  £76.2m (GMR.L)

The developer and licensor of mobile focused gaming content announced that its subsidiary, Alchemybet Limited, has been awarded an iGaming Supplier license to supply games within the Canadian province of Ontario ahead of the opening of the province’s regulated iGaming market on 4 April 2022. Gaming Realms’ entry into the Canadian iGaming market marks a significant milestone for the Group, presenting a long-term growth opportunity as the Company focuses on providing its Slingo Originals game content to Ontario’s licensed online casino operators. With a population of 15m, Ontario is larger than any State within the U.S. that is currently licensed for iGaming. It is reasonable to expect that revenues will be higher than New Jersey, Michigan or Pennsylvania, where the Company is currently supplying its Slingo Originals content. The Company will launch its full games portfolio in Ontario and is now preparing for launch as the market opens. With regard to current trading, whilst early in the year, 2022 has started well with revenues in excess of management’s expectations, giving management confidence in the outlook.

Haydale Graphene 3.8p  £19.4m (HAYD.L)

The global advanced materials group, has signed a sales representation agreement with Hainan Hongshida Information Technology Co., Ltd.. The Agreement is for an initial period of two years and allows Hongshida to act as a non-exclusive sales representative for Haydale’s ceramic and silicon carbide products in China (including Hong Kong) and Taiwan. Under the Agreement, Hongshida has agreed to purchase a minimum of 200 kg of product from Haydale within the first year of the agreement increasing to 5,000kg in the second year. If all volume commitments are met, the minimum value of the contract would be $1.14m but may be considerably higher depending on the product mix. The Company anticipates that the sales would mainly fall into the financial year ending June 2024. Hongshida, located in China’s new free trade zone of Hainan Province, provides engineering and technology solutions across equipment manufacturing, electronic components, and machinery to customers in the Chinese civilian aviation and other industrial sectors.

Midatech Pharma 13.25p  £13m (MTPH.L)

The  drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines announced an extension of its existing R&D collaboration with Janssen Pharmaceutica NV (Janssen) originally announced on 21 July 2020. On 17 June 2021 the Company announced that, using its Q-Sphera technology, it had successfully encapsulated a proprietary Janssen experimental large molecule medicine and importantly preserved its functional integrity. The Company believes no other commercial or academic organisation has been able to successfully deliver any such experimental medicine over extended periods using methods capable of commercial scaling. Following the initial programme (MTX213), the collaboration has been extended to include another large molecule to the research performed by Midatech for Janssen. As with the MTX213 molecule, the work will concentrate on maximizing drug loading and optimizing in vitro duration of release for this undisclosed Janssen experimental molecule using the Midatech’s Q-Sphera technology. 

Phoenix Global Resources 4p  £111.5m (PGR.L)

The upstream oil and gas company, announces an update on its funding arrangements. As disclosed in the Company’s announcement of 29 December 2021, Mercuria stated its intention to provide financial support to the Company in order that the Company could continue to operate and service the Company’s liabilities as they fall due for the 12-month period from 14 September 2021, the date of the release of the interim results, and agreed to meet the Company’s cash needs for this period and not demand repayment of the Mercuria loans (principal and interest), whilst discussions between the parties to restructure the loans continue. The parties continue to discuss the restructure of the existing debt and whilst these discussions continue, Mercuria has agreed to further increase the bridging facility, which carries interest at US$ LIBOR plus 4% and is not convertible, by US$30m to US$97.5m.

Shanta Gold 9.875p  £103m (SHG.L)

Transformative drilling results deliver 37% increase in West Kenya Resource and confirm confidence in district scale potential. New potential confirmed at the Ramula target and 6 proximal targets; Results in a 37% increase in total resources at West Kenya to 1.6m ounces; Ramula target has an inferred unconstrained in-situ resource estimate of 433,900 ounces grading 2.08 g/t, using a cut-off grade of 0.7g/t Au; Ramula target maiden resource was completed using the Canadian National Instrument 43-101 guidelines (NI 43-101); Total of 19 mineralised sub-horizontal zones at Ramula modelled to 240 metres depth; Several  of the 19 zones include high grade inferred resources currently summing to 107,684 ounces grading 6.43 g/t using a cut-off grade of 3.0 g/t; Preliminary indications of favourable low stripping ratio; Ramula target lies in the West Kenya Project, 35 kilometres  from Isulu-Bushiangala (Liranda Region); Management reviewing an accelerated timeline to full economic assessment.

Sound Energy 1.525p  £24.8m (SOU.L)

Sound Energy, the Moroccan focused upstream gas company, announces an extension to the date by which the conditions to its binding gas sale and purchase agreement (the GSA) in respect of the Phase 2 development of the Tendrara Production Concession with Morocco’s state owned power Company ONEE (Office National de l’Electricite et de l’Eau potable) for the sale of natural gas from the Tendrara Concession in Eastern Morocco over a 10 year period are required to be satisfied by a further three months. The terms of the GSA were announced by the Company on 30 November 2021. The GSA remains conditional upon, inter alia: (i) all necessary authorisations and permits having been granted for the construction of the Phase 2 gas installations (ii) the final investment decision, when taken, by the Tendrara joint venture partners, being approved by the Moroccan Ministries of Transition Energy and Sustainable Development and Economy and Finance; and (iii) the entry by the Tendrara joint venture partners of an interconnection agreement with the operator of the GME Pipeline, and the commencement of works, for the connection of the Tendrara Production Concession to the GME Pipeline. Progress has been made in the preparation of pipeline entry agreements, term sheets for financing, approvals and FID and consequently all parties have agreed to a 90 day extension period to the GSA.

Tissue Regenix 0.36p  £25m (TRX.L)

The regenerative medical devices company, announces that it has signed an exclusive distribution agreement with Geistlich Biomaterials Italia, a subsidiary company of Geistlich Pharma AG, a global company with a focus on regenerative products for bone, cartilage and tissue, for the distribution of OrthoPure XT in Italy. The OrthoPure XT decellularised xenograft ligament utilises Tissue Regenix’s patented dCell® technology and is the only available non-human biologic graft indicated for certain ligament reconstruction procedures. OrthoPure XT was commercially launched in December 2020 after being awarded a CE Mark for revision of anterior cruciate ligament reconstruction procedures and reconstruction of other knee ligaments, including multiligament and primary procedures when the autograft is unacceptable. The biocompatible implant provides a biomechanically appropriate tissue scaffold for cellular repopulation and eventual regeneration. The multiyear distribution agreement covers Italy currently but also has the potential for extension to wider geographies. As part of the agreement, Geistlich has also committed to advance the clinical science surrounding OrthoPure XT which will be conducted at some of the leading institutions by clinicians in Italy.

Mothercare 11.02p  £62.2m (MTC.L)

Mothercare announces that all business in Russia, including shipment of all products has been suspended. Its local partner has confirmed that it will be immediately pausing operations in some 120 stores and online. Russia represents around 20-25% of Mothercare’s worldwide retail sales and was previously expected to contribute around £0.5m per month to Group profit. Mothercare is the owner of the global specialist brand that designs, sources and supplies products across clothing, equipment and other products for parents and young children around the world.

Versarien 22p  £42.7m (VRS.L)

The advanced engineering materials group and provider of graphene-enhanced cement admixture, today announces the launch of its “Lunar” lifestyle pods designed with sustainability and innovation at the core. Lunar is Versarien’s first 3D printed concrete product made with Cementene™, Versarien’s graphene-enhanced cement. The launch will see Neill Ricketts, CEO of Versarien, unveil a building printed with Cementene™, at the Company’s production facilities in Longhope, Gloucestershire. Known as Versarien Lunar, this is a milestone project for a 3D-concrete printed product with a graphene additive. The versatile pods can be used as an office, studio, gym, or leisure room. The pod’s wall design shows the level of detail, flexibility and precision that can be achieved with 3D-concrete printing. The launch of Lunar comes at a time where sustainability in construction has never been more scrutinised. The industry accounts for around 8% of global CO2 emissions and would be third for emissions in the world if it were a country, behind only the US and China. Since fewer materials are needed to achieve the same structural performance as ordinary concrete, incorporating graphene into concrete can enable faster completion of buildings, reducing costs and the carbon footprint.

*A corporate client of Hybridan LLP

This document has been prepared by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor. The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document. This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU (“MIFID II Directive”); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook).